Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Stimulated by retinoic acid gene 6 protein (STRA6) is a multi-transmembrane protein that serves as the primary cell-surface receptor for retinol-binding protein 4 (RBP4), the major carrier of vitamin A in the blood (UniProt, 2024). Unlike traditional transporters, STRA6 facilitates the bidirectional movement of retinol across the cell membrane and also functions as a signaling receptor, activating the JAK/STAT pathway upon RBP4 binding (PubMed, 2021). It plays a critical role in embryonic development, particularly in the formation of the eyes, lungs, and heart, and its deficiency leads to Matthew-Wood syndrome (NIH, 2023). In adults, STRA6 is implicated in metabolic diseases such as obesity and type 2 diabetes through its role in RBP4-mediated insulin resistance (PubMed, 2022). Therapeutic strategies targeting the STRA6-RBP4 axis are being explored for treating metabolic disorders and certain cancers where STRA6 is overexpressed (ClinicalTrials.gov, 2024).
Antagonism of retinol-binding protein 4 (RBP4) to prevent its binding to STRA6, thereby inhibiting retinol uptake and downstream signaling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stimulated by retinoic acid gene 6 protein (STRA6).